-Luka Milas Researcher Activity Profile

Research Author Detailed Information 

Luka Milas Publication Rate By Year

Luka Milas has published 3 paper(s) in 2006, 13 paper(s) in 2007, 1 paper(s) in 2008, for a total of 17 research publications in total.

Luka L Milas Author Information

LAST NAME: milas

FIRST NAME: Luka

INITIALS: l

AFFILIATION:

Papers

Luka Milas's Publication Record

1. Combination of radiotherapy with EGFR antagonists for head and neck carcinoma. Year Published: 2007
Department of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
2. Early detection of chemoradioresponse in esophageal carcinoma by 3'-deoxy-3'-3H-fluorothymidine using preclinical tumor models. Year Published: 2006
Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, 77030, USA.
3. CpG oligodeoxynucleotides are potent enhancers of radio- and chemoresponses of murine tumors. Year Published: 2006
Department of Experimental Radiation Oncology, The University of Texas, Houston, TX 77030-4009, USA. kmason@mdanderson.org <kmason@mdanderson.org>
4. Importance of maintenance therapy in C225-induced enhancement of tumor control by fractionated radiation. Year Published: 2007
Department of Experimental Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030-4009, USA. lmilas@mdanderson.org
5. 130-nm albumin-bound paclitaxel enhances tumor radiocurability and therapeutic gain. Year Published: 2007
Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030-4009, USA.
6. Polymeric retinoid prodrug PG-4HPR enhances the radiation response of lung cancer. Year Published: 2007
Division of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
7. Modulation of tumor radiation response with G3139, a bcl-2 antisense oligonucleotide. Year Published: 2007
Department of Experimental Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Unit 066, Houston, TX 77030-4009, USA.
8. Integrating radiotherapy with epidermal growth factor receptor antagonists and other molecular therapeutics for the treatment of head and neck cancer. Year Published: 2007
Department of Experimental Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
9. Targeted Therapy Against VEGFR and EGFR With ZD6474 Enhances the Therapeutic Efficacy of Irradiation in an Orthotopic Model of Human Non-Small-Cell Lung Cancer. Year Published: 2007
Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX; Department of Experimental Radiation Oncology, MD Anderson Cancer Center, Houston, TX.
10. Integrating radiotherapy with epidermal growth factor receptor antagonists and other molecular therapeutics for the treatment of head and neck cancer. Year Published: 2007
Department of Experimental Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
11. Early detection of chemoradioresponse in esophageal carcinoma by 3'-deoxy-3'-3H-fluorothymidine using preclinical tumor models. Year Published: 2006
Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, 77030, USA.
12. Celecoxib Induced Tumor Cell Radiosensitization by Inhibiting Radiation Induced Nuclear EGFR Transport and DNA-Repair: A COX-2 Independent Mechanism. Year Published: 2007
13. Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer. Year Published: 2007
Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX 77030, USA.
14. Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer. Year Published: 2007
Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX 77030, USA.
15. INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase, enhances tumor response to doxorubicin. Year Published: 2008
Department of Experimental Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA, kmason@mdanderson.org.
16. Celecoxib induced tumor cell radiosensitization by inhibiting radiation induced nuclear EGFR transport and DNA-repair: a COX-2 independent mechanism. Year Published: 2007
17. Celecoxib induced tumor cell radiosensitization by inhibiting radiation induced nuclear EGFR transport and DNA-repair: a COX-2 independent mechanism. Year Published: 2007
Division of Radiobiology and Molecular Environmental Research, Department of Radiation Oncology, University of Tübingen, Tübingen, Germany. klaus.dittmann@uni-tuebingen.de